We studied the transient appearance of creatine kinase (EC 2.7.3.2) isoenzyme BB, as measured by electrophoresis, in serum or plasma from 19 patients who had just experienced cardiac or respiratory arrest. Creatine kinase BB activity was greatest 0.5 to 3 h after the arrest, with values (measured at 30#{176} C) ranging from 3 to 27 U/L (mean, 7.8 U/L) in 18 patients who were successfully resuscitated. Elimination time for the isoenzyme ranged from 8 to 48 h (mean,20 h). Eliminationt112
The relatively rare appearance of CK-BB' in serum has been associated with prostatic carcinoma (1) (2) (3) , small-cell anaplastic carcinoma of the lung (3), adenocarcinoma (1,3), leukemia (4), chronic renal failure (5, 6), Reye's syndrome (7) , cerebral contusions (7), various types of head injuries (8, 9) , seizures with prolonged alteration of consciousness (10), acute cerebrovascular accidents (7, 10) , drug overdose with intubation (10), neonates (11-13), women 5-8 h postpartum (6) , coronary artery bypass surgery (14, 15), and cardiac arrest (7, 16) .
During an eight-month period we examined the CK isoenzyme content of blood from 19 consecutive patients (13 men, six women) who had experienced periods of unconsciousness directly attributable to interruptions in respiratory function, cardiac function, or both. In all 19 cases we found CK-BB in the initial blood specimens, which were drawn 0.3 to 3 h after adequate circulation and oxygenation were restored. In 12 cases from whom adequate numbers of serial blood specimens were collected we were able to document the transient appearance of CK-BB within the first 24 h after the cardiac or respiratory arrest and to contrast this timedependent behavior with that of CK-MM and CK-MB. In addition, we found that three patients demonstrated macro CK-I (a complex of CK-BB and IgG), in their first post-event blood specimen. To our knowledge, this is the first report of transient macro CK-I associated with the appearance and disappearance of CK-BB.
Clinical Laboratory and Coronary Care Unit, Valley General Hospital, 400 South 43rd St., Renton, WA 98055. 1 Nonstandard abbreviations: CK, creatine kinase (ATP:creatine N-phosphotransferase, EC 2.7.3.2); CK-BB, CK-MB, CK-MM, isoenzymes of CK; 11A, immunoinhibition assay; macro CK-I, a complex of IgO and CK-BB.
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Materials and Methods
Serum specimens from these patients were obtained when routine enzyme analysis was requested by the cardiologist. Lithium heparin-treated plasma was obtained when routine electrolyte assays were requested. Sodium heparin-treated plasma was obtained by centrifuging blood remaining after the tests for arterial blood-gas analysis. The serum and plasma specimens were stored at -20 #{176}C until analyzed.
Total CK was measured at 30 #{176}C with "CK-NAC" reagent (Worthington Diagnostics, Freehold, NJ 07728) or with "Single Vial CK-NAC" reagent (Bio-Dynamics/BMC, Indianapolis, IN 46250) with a routine method on the Microcentrifugal Analyzer (Instrumentation Laboratory, Lexington, MA 02173). We only used the CK-NAC Reagent from Worthington for measuring total CK in serum specimens; heparinized plasma gave falsely increased results owing to visible turbidity in the rotor cuvettes. We used the Single Vial CK-NAC reagent to measure total CK in both serum and heparinized plasma. We determined that this reagent yielded identical results for total CK in serum and plasma obtained from the same blood drawing. When we used a preincubation period of 180 s with the BMC reagent, results for total CK were identical with those obtained with the Worthington reagent (incubation period of 60 s). The normal reference interval for total CK was 50-140 U/L.
We determined CK-MB by immunoinhibition assay (11A) for serum specimens by using the Microcentrifugal Analyzer and CK-MB reagent (Harleco, Gibbstown, NJ 08027) with a previously described procedure (17), but we did not multiply the result by 2. Atypical CK was judged to be present when the proportion of CK-MB to total CK exceeded 15% and the CK-MB was >6 U/L. CK isoenzymes were determined in serum and plasma by the Helena method (Helena Laboratories, Beaumont, TX 77704) with Sclavo staining reagent (Sclavo, Inc., Wayne, NJ 07470) as previously described (11). Fluoride was added to give a final concentration of 60 mmol/L, so as to inhibit completely any adenylate kinase (EC 2.7.4.3) present (11).
The approximate biological half-life (t112)of CK-BB in the patients was estimated from data on one or more blood specimens collected after the specimen with the peak CK-BB activity. In drawing a decay curve we used the time interval between the peak CK-BB value and the intercept on the activity curve when the activity was one-half of the peak activity as an estimate of the t112.
Results
We found CK-BB activity in blood from all these 19 patients who had just had a cardiac or respiratory arrest. We could find no correlation between either the highest CK-BB activity measured (usually in the first blood speci- men), the t112, or the elimination time and the neurologic outcome of the patient (Table 1 ). This was complicated by the fact that eight of the resuscitated patients subsequently suffered fatal second or multiple cardiopulmonary arrests. Furthermore, we could find no correlation between the total time during which cardiopulmonary resuscitation was given to the patient and the neurologic or vital outcome. This is 
36
Hours After Arrest The lack of correlation between blood CK-BB activity and the outcome of the patient can also partly be explained by the probability that the actual maximum of CK-BB activity was not measured in any of the cases. There is a very fast rise and fall in blood CK-BB after an arrest, as shown in Figure 1 for case number 9, who suffered a myocardial infarction and ventricular fibrillation. The CK-BB had a peak value of approximately 7.4 UIL only 1.8 h after the arrest, followed by an extremely sharp drop toO U/L after 24 h. The transient appearance of CK-BB contrasts with the much slower rise and fall of CK-MB, which peaked at 15 h, and of CK-MM, which peaked at 25 h. Thus the exact timing for the true peak CK-BB activity could never be accurately determined for any of these patients because of the infrequent and variable blood-drawing schedules requested by the attending physicians after the cardiac or respiratory arrests in all 19 patients. Figures 2 and 3 show further evidence that the appearance of CK-BB in blood is not related to the appearance of CK-MB and CK-MM. Patient number 6 ( Figure 2 ) suffered a myocardial infarction and ventricular fibrillation. As a result the apparent peak CK-BB activity appears within 1 h after the cardiac arrest. Conversely, the CK-MB and CK-MM increase to their maxima about 14 h after the event and begin to decline, but increase again after the patient suffered a second myocardial infarction without a cardiac arrest. Patient number 11 ( Figure 3 ) suffered a myocardial infarction with a subsequent increase in CK-MB and CK-MM, peaking at about 18 h. At 17 h after the myocardial infarction the patient suffered a cardiac arrest due to ventricular fibrillation, and there was a very abrupt increase in CK-BB. In contrast, the arrest did not appear to affect the activity of either CK-MB or CK-MM. It can be seen that CK-BB increased to 12 UIL within the first hour after the arrest. Macro CK-I was also found in the initially collected blood specimen. The CK-BB appeared to increase to 18 U/L after 10 h, followed by a rapid decline. We do not know whether the CK-BB activity was even greater between the 1-h and 10-h specimens. The CK-MB rose to a peak value of 20 U/L after 12 h and then decreased.
However, the CK-MM increased to about 1400 U/ L after 24 h. The low CK-MB activity (<3% of the total CK) in the face of high CK-MM activity is characteristic of CK isoenzymes released from muscle trauma after resuscitation (18, 19) . Figure 5 illustrates the long t112 for elimination of CK-BB by patient number 17, a well-documented 14 h. The changes in CK-MM, CK-MB, and CK-BB seemed to parallel one another, in contrast to all other cases, in whom CK-BB changed independently of CK-MM and CK-MB. The mechanism for the simultaneous release of all three CK isoenzymes in this case is unknown.
Routine measurements of the CK-MB activity by HA in six cases resulted in detection of atypical CK (CK-BB, macro CK-I, or mitochondrial CK) in the first blood specimen drawn after the cardiac or respiratory arrest, as shown in Figure 6 . Atypical CK was detected in the blood specimen when the ratio of CK-MB (by HA) to total CK equalled or exceeded 15% and the CK-MB (by HA) activity was >6 U/L. Blood specimens drawn after the first specimen contained much lower activities of CK-BB, the proportion of CK-MB to total CK being <3%. Patient number 6, who suffered a myocardial infarction at the time of the arrest and a second infarction 30 h later, demonstrated ratios between 1.5% and 8% after the first blood specimen. 
Discussion
There is a remarkable contrast between the kinetics for release of CK-BB after a period of anoxia vs the release of CK-MM and CK-MB after injury to striated muscle or myocardium. There appears to be a short transient release of CK-BB into the blood stream, peaking within about an hour after reoxygenation and restoration of circulation in an arrest patient. From data on those cases from whom an adequate number of blood specimens were collected, the decrease of CK-BB appears to have a half life of about 5.5 h (SD 1.2 h, n = 11). Complete disappearance of CK-BB required about 20 h (SD 13 h, n = 12).This contrasts with the 18 to 24 h required for CK-MB to reach its maximum and at least 48 h for it to be cleared after a myocardial infarction (20,21). Both the mechanism of the quick release of CK-BB after resuscitation of an arrest patient and the source of the enzyme are unknown.
Landaas et al. (14) measured CK-BB in serum after aortocoronary bypass surgery. They used a very specific antibody for CK-BB, derived from human macro CK-I (22) . There was no cross reaction with CK-MB.
CK-BB
was greatest about 3 h after the start of surgery, the peak concentrations being 7.5 to 15.5 g/L. If a conversion factor of 0.5 U per microgram (14) is used, the peak CK-BB would be 3.75 to 7.8 U/L, values that compare favorably with the range of 3 to 23 UIL for the 18 successfully resuscitated patients we studied. One patient, case no. 19, displayed a peak CK-BB activity of 87 U/L. He had head injury, hypothermia, and a long period of unsuccessful resuscitation (300 mm) and is not characteristic of the other cardiac-or respiratory-arrest patients in our study.
Using an antibody for CK-BB that showed 1% cross reactivity for CK-MB, Zweig and Van Steirteghem (15) also measured CK-BB in patients after cardiac surgery, usually cardiopulmonary bypass procedures.
They found CK-BB values to be highest on the same post-surgery day, the mean being 22 g/L. This is equivalent to an activity of about 11 U/L and compares reasonably well with the peak CK-BB activity, 7.8 U/L, reported by Landaas et al. (14) for patients undergoing coronary artery bypass surgery and with the mean value for peak CK-BB activity that we found after cardiac or respiratory arrest:
7.8 U/L. The rapid decrease in CK-BB after coronary artery bypass surgery reported by Landaas et al. (14) (t112,2 h ) is similar to the mean t1,2 that we report here for cardiopulmonary arrest patients, 5.5 h. The approximate t1,2 from data reported by Zweig appears to be longer, about 24 h; this may be explained by the fact that CK-MB increases more slowly than CK-BB after coronary artery bypass surgery (14) and can cross react with their antibody (15) .
Our inability to correlate the peak CK-BB activity or its duration after cardiopulmonary arrest with the neurologic or vital outcome of the patient contrasts with the conclusion reported by Longstreth et al. (16) . They measured CK-BB in serum from 52 patients after resuscitation from cardiopulmonary arrest and suggested that if CK-BB was detected within 6 h after the arrest the prognosis for complete recovery was poor. Our two patients with long t1,2 for CK-BB elimination survived (case numbers 11 and 17). However, Longstreth et al. (16) suggested that the CKBB appearing in blood after cardiopulmonary arrest is not derived from the brain, because they observed that "the initial serum CK-BB (measured after the arrest) did not correlate with the outcome of the patient." They found that cerebrospinal fluid CK-BB appeared to be a better predictor of neurologic outcome when this fluid was available for study, as was also reported by Vaagenes et al. (23) .
CK-BB appeared in the blood immediately after a cardiopulmonary arrest (0.5 to 3 h) in 100% of the cases we studied. This is in contrast to the observation by Kaste et al. (7) that CK-BB was present in serum of four of nine patients who experienced cardiac arrest with brain damage. However, the activities detected in the four patients ranged from 3 to 14 UIL (at 25 #{176}C), which compares well with the mean peak CK-BB activity of 7.8 U/L that we found in 18 patients, excluding case no. 19.
There are contrasting conclusions regarding the validity with which serum CK-BB values predict the degree of brain damage after head injury. This appears to be related to the method for CK-BB detection. Using electrophoresis to separate CK isoenzymes, Karpman et al. (9) concluded that serum CK-BB was not an accurate indicator of brain damage after head injury. However, using a radioimmunoassay, Phillips et al. (8) found increased concentrations of CK-BB in every patient they studied who had evidence of cerebral laceration, bruising, or swelling.
CK-BB is very unstable in blood at 37 #{176}C, and this may have a direct bearing on the ability to use CK-BB activity in blood as a reliable index for predicting the diagnosis or prognosis of any disease whatsoever.
Lott and Heinz (24) have clearly demonstrated that CK-BB is both inactivated and converted to a form of CK that migrates similar to CK-MB. Inactivation studies of crude CK-BB in rat-brain extract added to serum at 37 #{176}C suggest a t1,2 of no longer than 1 h, with both inactivation and conversion at pH 7.5. Other estimates of CK-BB stability range from 1 to 5 h (25). The mean ti,2 that we observed was 5.5 h in 11 of 13 patients for whom we had an adequate number of specimens to make a judgment. The two patients who had a relative rapid resuscitation compared to the other patients (case numbers 11 and 17) demonstrated much longer half-lives for the decrease of CK-BB, 14 and 16 h, which may suggest an ongoing or more sustained release of CK-BB after their arrests.
As is well known (17, 19, 26) , CK-BB can interfere with the measurement of CK-MB (by HA) by giving a false positive or atypical CK result. To our knowledge, the transient appearance of atypical CK after cardiac or respiratory arrest has not be observed heretofore. Increased activity of CK-MB (by HA) immediately after cardiac or respiratory arrest was detected when the blood-drawing procedure was changed. It is known that an increase and decrease in CK-MB (by HA) is considered diagnostic for myocardial infarction (19-21, 26-28) . Still, the first blood specimen is usually not drawn until about 10 to 12 h after a patient is admitted to the coronary-care unit, so as to allow time for the CK-MB to enter the blood stream. The cardiologists in charge of our coronary-care unit reasoned that a value for the CK-MB (by HA) activity could be obtained earlier-in fact, immediately after the suspected myocardial infarction-in order to identify that proportion of the patient population, approximately 2-3%, who have sustained levels of atypical CK high enough to interfere with a diagnosis for myocardial infarction. Thus a "baseline" for CK-MB (by HA) can be determined for all patients entering the coronarycare unit in order that the "rise and fall" in activity can be clearly observed. The transient atypical CK found in the first blood specimen drawn after admission to the emergency room ( Figure 6 ) when one is measuring CK-MB by HA is a result of the transient appearance of CK-BB after a period of anoxia resulting from a cardiac or respiratory arrest, whether or not a myocardial infarction also occurred.
We conclude that a short burst of CK-BB enters the blood during resuscitation of patients who have experienced a period of anoxia due to a cardiac or respiratory arrest. The highest activity of CK-BB measured for each of the 19 patients that we studied did not correlate with the eventual outcome. We attribute this to (a) a very sharp peak of activity occurring within 0.5 to 3 h after the cardiac or respiratory arrest and the near impossibility of obtaining a blood specimen at exactly the time when the CK-BB activity reaches its highest value, and (b) the very fast metabolism of CK-BB in blood at 37 #{176}C, which results in effective elimination t112 values of CK-BB activity of about 2-5 h. Furthermore, there may be a large individual variation in the rate at which a given amount of CK-BB activity is eliminated. The use of immunoassays with antibody specific for CK-BB (only) may be the best approach to further defining the relationship between the CK-BB released after a period of anoxia resulting from a cardiac or respiratory arrest and the neurologic damage and vital outcome for the patient.
